In a major breakthrough in the nation's discovery of the indigenous vaccine to treat the COVID-19 pandemic, India has seen a positive sign from one of the indigenous vaccine candidates 'Covaxin' in treating the viral infection as it hasn't jabbed with an adverse effect for the volunteers to whom it was administered. 

According to the reports, the human trial of Bharat Biotech's anti-COVID-19 vaccine Covaxin has started at Haryana's Rohtak's Post-Graduate Institute of Medical Sciences on Friday during which the vaccine candidate was injected to three subjects to ascertain the effect in the human body. 

Taking to Twitter, Haryana Health Minister Anil Vij said "Three subjects were enrolled today. All have tolerated the vaccine very well. There were no adverse effects". The doctors attached to the Rohtak's Institute of Medical Sciences said that three volunteers were administered the vaccine as part of the first phase of the clinical trial.  

Human trial with Corona vaccine (COVAXIN) of Bharat Biotech started at PGI Rohtak today. Three subjects were enrolled today. All have tolerated the vaccine very well. There were no adverse efforts.

— ANIL VIJ MINISTER HARYANA (@anilvijminister) July 17, 2020

The process would likely take six months and the doctors further stated that the effect of the vaccine would be assessed over the next three months from the antibodies generated and the reaction it has caused. As the next step, the vaccine will be administered to more people across the testing sites and they will be also be observed at regular intervals like the first three subjects.

The volunteers enrolling in the human trial have been in the age group from 30 to 40 years. While addressing the reporters amid the development, Haryana Health Minister Anil Vij said that more vaccine candidates will be enrolled for the trial in the upcoming days. The reports say that in the second phase of the human trial, the vaccine dosage would be increased. 

It has been the first human trial conducted by the Bharat Biotech on the vaccine 'Covaxin' after getting consent for starting the trial from the Drug Controller General of India (DCGI). Hyderabad based Bharat Biotech has collaborated with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV). 

However, according to the reports released on Saturday, Bharat Biotech has said the first phase of testing has begun on 375 people. Twelve hospitals in different parts of the country have been carrying out the tests and human trials. Bharat Biotech is one of the seven Indian firms that have been working on COVID-19 vaccines.

Bharat Biotech and Zydus are the two drug firms that have been approved by the DCGI to carry out the human trials and on Wednesday, Zydus had started the human trials for its vaccine candidate ZyCoV-D and the company said it would be enrolling over 1,000 subjects across the several clinical study sites in India. Upon proving its curability, these vaccines will become India's indigenous vaccines to cure the COVID-19 pandemic.